Newly registered or updated clinical trials in aging and longevity research.
| Trial ID | Intervention | Condition | Phase | Status |
|---|---|---|---|---|
| NCT06313360 | OSK therapy (partial reprogramming) – Press Release | Glaucoma / NAION | I | First patient dosed (May 2026) |
| NCT06836609 | ALN-CIDEB (RNAi) | MASLD / MASH (fatty liver disease) | I | Recruiting |
| NCT04375657 | Thymus regeneration (growth hormone + metformin + DHEA) | Immunosenescence | II | Recruiting (ages 40‑80) |
| NCT04785300 | Dasatinib + Quercetin (D+Q) | Alzheimer's disease (mild) | I | Safety data reported (June 2026) |
📅 Updated monthly. Source: ClinicalTrials.gov. Subscribe for monthly digest.